Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma Citius...
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program PR...
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration...
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences PR Newswire...
HC Wainwright reissued their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR Free Report) in a research report sent to investors on Wednesday, Benzinga reports. The brokerage...
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and...
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma Citius...
Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J...
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR Free Report) Investment analysts at HC Wainwright issued their FY2024 earnings per share estimates for shares of Citius Pharmaceuticals in a...